DEF: Lifecore Biomedical Sets 2025 Annual Meeting Agenda

Lifecore Biomedical, Inc. announces its 2025 Annual Meeting of Stockholders to be held virtually on October 29, 2025, addressing director elections, auditor ratification, and executive compensation.

Summary

• The 2025 Annual Meeting of Stockholders will be held virtually on Wednesday, October 29, 2025, at 10:30 a.m. (Central Time).
• Stockholders will vote on the election of nine directors, the ratification of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, and a non-binding advisory proposal approving executive compensation.
• The company's fiscal year has been changed from the last Sunday of May to December 31, effective for the December 31, 2025 calendar period, with a transition report on Form 10-K/T covering May 26, 2025, to December 31, 2025.
• Adjusted EBITDA for fiscal year 2025 was $19.5 million, which failed to meet the minimum target of $20.5 million, primarily due to unexpected legal, auditing, and legacy costs.
• The company reported a GAAP net loss of $(38.7) million for the fiscal year ended May 25, 2025.
• Material weaknesses in internal control over financial reporting persisted for fiscal years ended May 26, 2024, and May 25, 2025.
• A $24.3 million stock sale was successfully completed in October 2024 at $4.10 per share.
• Stockholders approved the removal of the Exchange Limit cap on the conversion of Series A Preferred Stock into Common Stock on April 10, 2025.
• An ongoing legal proceeding with 22NW Fund, LP seeks money damages and specific performance related to alleged misrepresentations and registration delay fees.

Sentiment

Score: 4

Explanation: While there are positive governance updates and a successful capital raise, the company reported a significant net loss, missed its Adjusted EBITDA target, and continues to face material weaknesses in internal controls and ongoing legal proceedings, indicating significant operational and financial challenges.

Positives

• Stockholders expressed strong support for the 2024 executive compensation program, with 99.1% approval in a non-binding advisory vote.
• The company successfully completed a $24.3 million stock sale in October 2024, enhancing its financial position.
• Stockholders approved the removal of the Exchange Limit cap on Series A Preferred Stock conversion, resolving a significant restriction.
• The executive and leadership team is being strategically realigned to focus on the CDMO business.
• New executive compensation packages are heavily weighted towards performance-based equity awards (PSUs) to align executive interests with stockholders.
• The Board maintains a majority of independent directors and adheres to sound corporate governance practices.

Negatives

• Adjusted EBITDA for fiscal year 2025 was $19.5 million, failing to meet the minimum target of $20.5 million, largely due to unexpected legal, auditing, and legacy costs.
• The company reported a GAAP net loss of $(38.7) million for the fiscal year ended May 25, 2025.
• Material weaknesses in internal control over financial reporting continued to exist for fiscal years ended May 26, 2024, and May 25, 2025.
• An ongoing legal proceeding with 22NW Fund, LP seeks money damages and specific performance, creating legal and financial uncertainty.
• The company accrued $1.0 million in monetary penalties for registration delay fees in fiscal year 2025, with $4.5 million in total outstanding penalties as of May 25, 2025.
• Discretionary payouts under the 2025 Bonus Plan were approved despite not meeting the Adjusted EBITDA target, potentially diluting the pay-for-performance philosophy.
• One executive officer, Ryan D. Lake, failed to timely file a Form 4 report.

Risks

• Ongoing legal proceedings could result in significant financial losses, reputational damage, or divert management attention and resources.
• Persistent material weaknesses in internal control over financial reporting could lead to further financial misstatements, regulatory non-compliance, or impact investor confidence.
• Failure to meet Adjusted EBITDA targets indicates operational challenges and could negatively impact future profitability and stock performance.
• Accrued monetary penalties for registration delays under the Registration Rights Agreement represent a financial liability.
• The competitive labor market in the life sciences industry could challenge the company's ability to attract and retain key executive talent.
• The value realized from performance stock unit (PSU) awards is contingent on sustained stock price improvement, posing a risk to executive compensation if targets are not met.

Future Outlook

The company expects to change the timing for its 2026 Annual Meeting by more than 30 days from the date of the 2025 Annual Meeting due to the fiscal year change to December 31. It plans to file annual reports for twelve-month periods ending December 31, beginning with the year ending December 31, 2026. Public announcements of 2026 Annual Meeting dates and applicable deadlines will be made when known.

Management Comments

• The 2025 program reflects the ongoing transition in the Lifecore CDMO business, including a Chief Financial Officer transition as part of the realignment of our executive and leadership team to our CDMO business.
• The Compensation Committee believes that our annual RSU awards are aligned to the general trend toward fixed-value, share awards.
• The Company believes that the risks arising from its compensation policies and practices are not reasonably likely to have a material adverse effect on the Company.

Industry Context

Lifecore Biomedical is undergoing a significant strategic transition to operate as a standalone, fully integrated Contract Development and Manufacturing Organization (CDMO). This shift is reflected in the realignment of its executive team and the design of its compensation programs, which are tailored to the life sciences sector. The company's peer group for compensation analysis includes other CDMOs, Contract Research Organizations (CROs), medical technology, and commercial pharmaceutical products and services companies, indicating its focus on specialized contract services within the broader healthcare industry.

Comparison to Industry Standards

• The Compensation Committee uses peer group information from the life sciences sector (including CDMOs, CROs, medical technology, and commercial pharmaceutical products/services companies) to provide context for executive compensation decisions.
• Lifecore's market capitalization of approximately $162 million was below the median market capitalization of its peer group companies (approximately $209 million) at the time the fiscal year 2025 peer group was confirmed.
• The base salary and target annual cash compensation for CEO Paul Josephs were below the median of the peer group CEO data, in recognition of his significant new-hire equity awards.
• CFO Ryan D. Lake's base salary and target annual cash compensation approximated the median of peer group CFO data, but his significant new-hire equity awards exceeded the median for the CFO position.
• No specific comparisons of the company's financial performance (e.g., revenue growth, profitability, or internal control effectiveness) against industry benchmarks or competitors are provided in the filing.

Management Changes

Corporate Governance

Legal Proceedings

• On December 23, 2024, 22NW Fund, LP filed a complaint against the Company, two former officers, and five former or current directors in the Commercial Division of the Supreme Court of the State of New York, New York County.
• The complaint seeks money damages for alleged material misrepresentations, alleged breaches of express representations in the stock purchase agreement, and registration delay fees owed under a registration rights agreement.
• The complaint also seeks the equitable remedy of specific performance, requesting an order compelling the company to file a proxy statement and hold a stockholder meeting to approve the removal of the current cap on Series A Preferred Stock conversion.
• On February 24, 2025, the company filed a motion to dismiss all claims against it except for those relating to registration delay fees; individual defendants filed separate motions to dismiss.
• Motions were fully briefed on April 9, 2025, and the Court has not yet scheduled a hearing.
• On March 27, 2025, the Court issued a case management order setting forth an initial schedule for discovery, which is ongoing.
• The company intends to vigorously defend itself and its former officers and directors; any potential loss is not currently probable or estimable, but registration delay fees have been accrued.

Related Party Transactions

• In October 2024, the company entered into a Stock Purchase Agreement, selling 5,928,775 shares of Common Stock for $24.3 million at $4.10 per share. Entities affiliated with director Christopher S. Kiper (Legion Partners Asset Management, LLC) purchased 1,463,414 shares for $6.0 million, and entities affiliated with director Nelson Obus (Wynnefield Capital, Inc.) purchased 292,683 shares for $1.2 million.
• On January 9, 2023, the company issued and sold 38,750 shares of Series A Convertible Preferred Stock for $38.8 million to qualified investors, including Legion Partners entities (affiliated with director Christopher S. Kiper), Wynnefield entities (affiliated with director Nelson Obus), and 22NW entities (affiliated with former director Nathaniel Calloway).

Stakeholder Impact

• **Shareholders**: Will participate in the 2025 Annual Meeting to vote on key proposals. Impacted by the company's financial performance (net loss, missed EBITDA target), ongoing legal proceedings, and the successful capital raise. The removal of the Series A Preferred Stock conversion cap could lead to increased common stock outstanding upon conversion.
• **Employees**: Executive team realignment has led to changes in key personnel, including the departure of the former CFO and the hiring of new executives. Compensation programs are designed to attract and retain talent, with a focus on performance-based incentives.
• **Creditors**: The $24.3 million capital raise in October 2024 improved the company's liquidity. Holders of Series A Preferred Stock have senior ranking with respect to dividends, distributions, and payments on liquidation.
• **Regulatory Bodies**: The company is subject to SEC and Nasdaq listing requirements, with identified material weaknesses in internal controls and ongoing legal proceedings requiring close attention and compliance.

Next Steps

• Hold the 2025 Annual Meeting of Stockholders virtually on October 29, 2025.
• Report financial results for a transition period from May 26, 2025, to December 31, 2025, on a Transition Report on Form 10-K/T.
• File annual reports for twelve-month periods ending December 31, beginning with the year ending December 31, 2026.
• Make a public announcement of dates and deadlines for the 2026 Annual Meeting when known.
• Continue to vigorously defend against the legal action filed by 22NW Fund, LP.
• Address and remediate the identified material weaknesses in internal control over financial reporting.

Key Dates

Recommendation

The company is undergoing a significant strategic transition to a pure-play CDMO, which is a positive long-term direction. The recent capital raise and strong stockholder support for compensation indicate some underlying confidence. However, the persistent material weaknesses in internal controls, the ongoing legal dispute with 22NW Fund, LP, and the failure to meet Adjusted EBITDA targets for fiscal year 2025 present considerable headwinds and uncertainties. While the long-term potential of the CDMO business exists, the current operational and legal challenges warrant a cautious approach. Investors should monitor the remediation of internal control weaknesses, the outcome of the lawsuit, and the company's ability to achieve its financial targets in the new fiscal year structure before considering a stronger position.

Keywords

Lifecore Biomedical, LFCR, SEC filing, proxy statement, annual meeting, corporate governance, executive compensation, director election, auditor ratification, financial reporting, internal controls, Adjusted EBITDA, net loss, stock sale, capital raise, legal proceedings, Series A Preferred Stock, CDMO, life sciences, risk management